Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2015 Feb 5;125(6):992-8. doi: 10.1182/blood-2014-06-583369. Epub 2014 Nov 24.

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Author information

1
Division of Hematology.
2
Biomedical Statistics and Informatics, and.
3
Division of Hematopathology, Mayo Clinic, Rochester, MN;
4
College of Medicine, University of Iowa, Iowa City, IA;
5
Wilmot Cancer Institute, University of Rochester, Rochester, NY;
6
Fred Hutchinson Cancer Center/South West Oncology Group Statistical Center, Seattle, WA; and.
7
Division of Epidemiology, Mayo Clinic, Rochester, MN.

Abstract

Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients (n = 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group (SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist (IL-1RA) (P = .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P = .015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P = .013, .042, and .0012) were associated with a poor EFS.

PMID:
25422100
PMCID:
PMC4319239
DOI:
10.1182/blood-2014-06-583369
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center